Display options
Cite
Cavo A, Rubagotti A, Zanardi E, et al. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018;10:1758834017745819doi: 10.1177/1758834017745819.
Cavo, A., Rubagotti, A., Zanardi, E., Fabbroni, C., Zinoli, L., Di Meglio, A., Arboscello, E., Bellodi, A., Spallarossa, P., Cattrini, C., Messina, C., & Boccardo, F. (2018). Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Therapeutic advances in medical oncology, 101758834017745819. https://doi.org/10.1177/1758834017745819
Cavo, Alessia, et al. "Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes." Therapeutic advances in medical oncology vol. 10 (2018): 1758834017745819. doi: https://doi.org/10.1177/1758834017745819
Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes. Ther Adv Med Oncol. 2018 Jan 09;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018. PMID: 29383035; PMCID: PMC5784574.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Med Oncol. 2018 Jan 09;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018.

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Therapeutic advances in medical oncology

Alessia Cavo, Alessandra Rubagotti, Elisa Zanardi, Chiara Fabbroni, Linda Zinoli, Antonio Di Meglio, Eleonora Arboscello, Andrea Bellodi, Paolo Spallarossa, Carlo Cattrini, Carlo Messina, Francesco Boccardo

Affiliations

  1. Academic Unit of Medical Oncology, San Martino Polyclinic Hospital, Institute for Cancer Research and Treatment, Genoa, Italy.
  2. Academic Unit of Internal Medicine 3, San Martino Polyclinic Hospital, Institute for Cancer Research and Treatment, Genoa, Italy.
  3. Clinic of Cardiovascular Disease, San Martino Polyclinic Hospital, Institute for Cancer Research and Treatment, Genoa, Italy.
  4. Academic Unit of Medical Oncology, San Martino Polyclinic Hospital, Institute for Cancer Research and Treatment, L.go R. Benzi 10, 16132, Genoa, Italy.

PMID: 29383035 PMCID: PMC5784574 DOI: 10.1177/1758834017745819

Abstract

BACKGROUND: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival outcomes.

METHODS: This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre-

RESULTS: Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) ⩾ 10 ng/ml (

CONCLUSIONS: Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.

Keywords: abiraterone acetate; cardiovascular adverse events; hypokalemia; metastatic castration-resistant prostate cancer; obesity; safety

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. Am J Clin Oncol. 2015 Oct;38(5):479-82 - PubMed
  2. Heart. 2003 Nov;89(11):1363-72 - PubMed
  3. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  4. Eur Urol. 2013 May;63(5):800-9 - PubMed
  5. J Clin Oncol. 2008 Mar 1;26(7):1148-59 - PubMed
  6. Ann Acad Med Singapore. 1994 Mar;23(2):129-38 - PubMed
  7. N Engl J Med. 2017 Jul 27;377(4):338-351 - PubMed
  8. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed
  9. BJU Int. 2015 May;115(5):764-71 - PubMed
  10. Proc Natl Acad Sci U S A. 1931 Dec;17(12):684-8 - PubMed
  11. Eur Urol. 2015 Jul;68(1):42-50 - PubMed
  12. Lancet Oncol. 2013 Feb;14(2):149-58 - PubMed
  13. Clin Genitourin Cancer. 2016 Feb;14 (1):48-55 - PubMed
  14. N Engl J Med. 2015 Aug 20;373(8):737-46 - PubMed
  15. Lancet Oncol. 2012 Oct;13(10):983-92 - PubMed
  16. Annu Rev Med. 2010;61:301-16 - PubMed
  17. Cancer Prev Res (Phila). 2011 Apr;4(4):486-501 - PubMed
  18. PLoS One. 2011 Apr 28;6(4):e19059 - PubMed
  19. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  20. Int J Clin Pract. 2011 Nov;65(11):1180-92 - PubMed
  21. BJU Int. 2005 Dec;96(9):1241-6 - PubMed
  22. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  23. Anticancer Drugs. 2017 Jan;28(1):110-115 - PubMed
  24. Cancer Med. 2016 Jul;5(7):1381-7 - PubMed
  25. N Engl J Med. 2013 Jan 10;368(2):138-48 - PubMed
  26. Lancet Oncol. 2015 Feb;16(2):152-60 - PubMed
  27. BJU Int. 2012 Aug;110(4):492-8 - PubMed
  28. Ther Adv Med Oncol. 2016 Sep;8(5):323-30 - PubMed
  29. Cancer Res. 2008 Jun 1;68(11):4447-54 - PubMed
  30. Can Urol Assoc J. 2016 Nov-Dec;10 (11-12Suppl7):S245-S247 - PubMed
  31. J Urol. 2015 Nov;194(5):1277-84 - PubMed
  32. Eur Urol. 2014 May;65(5):884-6 - PubMed
  33. Lancet. 2000 Apr 29;355(9214):1491-8 - PubMed
  34. Drug Des Devel Ther. 2012;6:13-8 - PubMed
  35. N Engl J Med. 2017 Jul 27;377(4):352-360 - PubMed

Publication Types